

PRODUCT MONOGRAPH

**Pr MYLAN-GLICLAZIDE
(gliclazide tablets, BP)**

80 mg Tablets

**Hypoglycemic sulfonylurea
Oral hypoglycemic agent**

MYLAN PHARMACEUTICALS ULC
85 Advance Road,
Etobicoke Ontario
M8Z 2S6

Date of Revision: January 12, 2017

Control Number: 201111

PRODUCT MONOGRAPH

Pr MYLAN-GLICLAZIDE (gliclazide tablets, BP) 80 mg Tablets

Oral hypoglycemic agent

ACTIONS AND CLINICAL PHARMACOLOGY

MYLAN-GLICLAZIDE (gliclazide) is a hypoglycemic agent of the sulfonylurea group.

The hypoglycemic action of MYLAN-GLICLAZIDE (gliclazide) is related to an improvement in insulin secretion from the functioning beta cells of the pancreas. It potentiates the insulin release, improves the dynamics of insulin.

Hemobiological properties of gliclazide have been observed in pharmacology studies. These are attributed to gliclazide action on the platelet behaviour, prostaglandin equilibrium and fibrinolysis.

Gliclazide is rapidly absorbed from the gastro-intestinal tract and the plasma peak of gliclazide occurs between 4 and 6 hours. In man it is highly bound to plasma proteins, about 94%. The mean elimination half-life in man approximates 10.4 hours.

Following oral administration the unchanged gliclazide in plasma is extensively metabolized with little of the unchanged compound (< 1%) appearing in the urine.

Gliclazide metabolites and conjugates are primarily eliminated via kidneys: 60 to 70% and about 10 to 20% via faeces.

Some five principal metabolites have been identified in urine, essentially oxidized and hydroxylated derivatives, some as glucuronic acid conjugates.

INDICATIONS

Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.

CONTRAINDICATIONS

- Known hypersensitivity or allergy to MYLAN-GLICLAZIDE, other sulfonylureas, sulfonamides, or to any of the excipients of this product (for a complete listing, see PHARMACEUTICAL INFORMATION, COMPOSITION section).
- Unstable and/or insulin dependent diabetes mellitus, particularly juvenile diabetes, diabetic ketoacidosis, diabetic pre-coma and coma.
- During stress conditions such as serious infection, trauma or surgery.
- In the presence of severe hepatic impairment.
- In the presence of severe renal impairment.
- Treatment with miconazole via systemic route or oromucosal gel (see DRUG INTERACTIONS).
- Pregnancy and lactation (see PRECAUTIONS, Pregnant Women and Nursing Mothers)

WARNINGS

The use of MYLAN-GLICLAZIDE (gliclazide) will not prevent the development of complications peculiar to diabetes mellitus.

Use of MYLAN-GLICLAZIDE (gliclazide) must be considered as treatment in addition to proper dietary regimen and not as substitute for diet.

The efficacy of gliclazide, in reducing glucose to the desired level decreases over a long period of time in many patients: this may be due to progression in the severity of the diabetes, or to a reduced response to treatment. If a loss of adequate blood glucose-lowering response to MYLAN-GLICLAZIDE is detected, the drug should be discontinued.

PRECAUTIONS

Patients selection and follow-up

Careful selection of patients is important. It is imperative that there be rigid attention to diet, careful adjustment of dosage and instruction of the patient on hypoglycemic reactions, their recognition, remedies and control as well as regular, thorough medical follow-up.

Since the effects of oral hypoglycemic agents on the vascular changes and other long-term sequelae of diabetes mellitus are not fully known, patients receiving such drugs must be closely observed for both short-and long-term complications. Periodic assessment of cardiovascular, ophthalmic, renal and hepatic status is advisable.

In patients stabilized on gliclazide therapy, loss of blood sugar control may occur in cases of acute intercurrent disease, in stressful situations such as trauma or surgery, or if used concomitantly with herbs such as St. John's Wort (*Hypericum perforatum*) preparations or any treatment that may interact with gliclazide metabolism (see DRUG INTERACTIONS & Drug-Herb Interactions). Under these conditions, discontinuation of MYLAN-GLICLAZIDE and administration of insulin should be considered.

Hematologic

Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD)-deficiency with sulfonylurea agents can lead to haemolytic anaemia. Since gliclazide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered.

Hepatic

The metabolism and excretion of sulfonylureas including gliclazide may be slowed in patients with impaired hepatic function. Isolated cases of impairment of liver function with cholestasis and jaundice, and hepatitis which can regress after withdrawal of the drug or may lead to life-threatening liver failure have been observed. Discontinue treatment if cholestatic jaundice appears. Therefore, MYLAN-GLICLAZIDE is contraindicated in patients with severe hepatic impairment (See CONTRAINDICATIONS and PRECAUTIONS, Monitoring and Laboratory Tests).

Renal

The metabolism and excretion of sulfonylureas including gliclazide may be slowed in patients with impaired renal function. If hypoglycemia should occur in such patients, it may be prolonged and appropriate management should be instituted. Therefore, Gliclazide is contraindicated in

patients with severe renal impairment (See CONTRAINDICATIONS and PRECAUTIONS Monitoring and Laboratory Tests).

Peri-Operative Considerations

In patients stabilized on gliclazide therapy, loss of blood sugar control may occur in cases of acute intercurrent disease or in stressful situations such as trauma or surgery. Under these conditions, discontinuation of MYLAN-GLICLAZIDE and administration of insulin should be considered.

Hypoglycemic reactions

As with other sulfonylurea drugs, manifestations of hypoglycemia including dizziness, lack of energy, drowsiness, headache and sweating have been observed and weakness, nervousness, shakiness and paresthesia have also been reported. Severe hypoglycemia can be induced by all sulfonylurea drugs. Particularly susceptible are elderly subjects, patients with impaired hepatic or renal function, those who are debilitated or malnourished and patients with primary or secondary adrenal insufficiency. Hypoglycemia is more likely to occur when caloric intake is inadequate or after strenuous or prolonged physical exercise. Some cases may be severe and prolonged. Hospitalisation may be necessary and glucose administration may need to be continued for several days. Hypoglycemia may be difficult to recognize in elderly patients and in patients receiving beta-blockers.

Possible other symptoms of hypoglycaemia are: intense hunger, lassitude, sleep disorders, agitation, aggression, poor concentration, reduced awareness and slowed reactions, depression, confusion, visual and speech disorders, aphasia, paresis, sensory disorders, feeling of powerlessness, loss of self-control, delirium, convulsions, shallow respiration, bradycardia, drowsiness and loss of consciousness, possibly resulting in coma and lethal outcome. In addition, signs of adrenergic counter-regulation may be observed: clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmia.

Usually, hypoglycaemic symptoms disappear after intake of carbohydrates (sugar). However, artificial sweeteners have no effect. Experience with other sulphonylureas shows that hypoglycaemia can recur even when measures prove effective initially.

If a hypoglycaemic episode is severe or prolonged, and even if it is temporarily controlled by intake of sugar, immediate medical treatment or even hospitalisation are required.

Treatment with gliclazide can have effects on ability to drive and use machines. Patients should be made aware of the symptoms of hypoglycaemia and should be careful if driving or operating machinery, especially at the beginning of treatment.

Other factors which increase the risk of hypoglycemia are: overdose of gliclazide, certain endocrine disorders (thyroid disorders, hypopituitarism and adrenal insufficiency) as well as withdrawal of prolonged and/or high dose corticosteroid therapy, severe vascular disease (severe coronary heart disease, severe carotid impairment, diffuse vascular disease) and concomitant administration of certain medicines (See DRUG INTERACTIONS).

Dysglycaemia

Fluoroquinolones should be used with caution in patients receiving MYLAN-GLICLAZIDE. Hypoglycaemia and hyperglycaemia have been reported in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. Careful monitoring of blood glucose is recommended in all patients taking MYLAN-GLICLAZIDE and a fluoroquinolone concomitantly. (See Drug Interaction)

Skin

Serious skin and hypersensitivity reactions including rash, pruritus, urticaria, angioedema, erythema, maculopapular rashes, bullous reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis) and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported.

Special Populations

Pregnant Women

Gliclazide is contraindicated in pregnancy. It is recommended that insulin be used during pregnancy in diabetic women (see CONTRAINDICATIONS).

Uncontrolled diabetes (gestational or not) is associated with a higher incidence of congenital abnormalities and perinatal mortality. Blood glucose control should be optimal around the time of conception to reduce the risk of congenital malformations.

Nursing mothers

The product is contra-indicated in breast-feeding mothers. Some sulfonylurea drugs are excreted in human milk although it is not known whether gliclazide is one of them. Because the potential for hypoglycemia in nursing infants may exist, the product is contra-indicated in breast-feeding mothers (see CONTRAINDICATIONS).

Pediatric use

Safety and effectiveness in children have not been established. MYLAN-GLICLAZIDE is therefore not recommended for use in children and adolescents.

Geriatrics

Efficacy and tolerance of gliclazide, prescribed using the same therapeutic regimen in subjects over 65 years, has been confirmed in clinical trials.

Severe hypoglycemia can be induced by all sulfonylurea drugs, particularly susceptible are elderly subjects.

Monitoring and Laboratory Tests

Measurement of glycated haemoglobin levels (or fasting venous plasma glucose) is recommended in assessing blood glucose control. Blood glucose self-monitoring is also recommended.

Blood glucose control in a patient receiving MYLAN-GLICLAZIDE treatment may be affected by fever, infection, surgical intervention or when used concomitantly with St. John's Wort (*Hypericum perforatum*) preparations. Closed monitoring is required in these patients. In some cases, it may be necessary to administer insulin.

Hepatic function should be assessed before initiating therapy and the liver function should be assessed periodically in patients with mild to moderately impaired hepatic function.

In patients with mild to moderately impaired renal function, renal function should be assessed periodically, blood and urine glucose should be regularly monitored. Measurements of glycated hemoglobin levels are recommended.

Elderly patients (malnourished, with impaired hepatic, renal, or adrenal function) will require periodic monitoring and special care.

DRUG INTERACTIONS

As a result of drug interaction, hypoglycemia may be potentiated when a sulfonylurea is used concurrently with agents such as: long-acting sulfonamides, tuberculostatics, clarithromycin, phenylbutazone, clofibrate, monoamine oxidase inhibitors, coumarin derivatives, salicylates, non-steroidal anti-inflammatory agents, probenecid, beta-blockers, miconazole (see CONTRAINDICATIONS), azole antifungal agents (oral and parenteral preparations), H₂-receptor antagonists, disopyramide and angiotensin converting enzyme inhibitors. In addition, while not approved for use with other antidiabetic agents, hypoglycaemia is potentiated when gliclazide is used in combination with other antidiabetic agents.

Certain drugs tend to induce hyperglycemia and may lead to loss of control of blood sugar control. These include diuretics (thiazides, furosemide), corticosteroids and tetracosactin, danazol, chlorpromazine, ritodrine/ salbutamol/ terbutaline (IV), oral contraceptives (estrogen plus progestogen) and nicotinic acid in pharmacologic doses.

Barbiturates should be used with caution in patients receiving an oral hypoglycemic agent since they may reduce the hypoglycemic effect.

Concomitant use of fluoroquinolones and MYLAN-GLICLAZIDE may cause hypoglycaemia and hyperglycaemia. Elderly patients may be more sensitive to this interaction. In case of concomitant use of MYLAN-GLICLAZIDE and a fluoroquinolone, the patient should be warned of this risk and the importance of blood glucose monitoring should be emphasized.

Combination with anticoagulant therapy (warfarin and other) must be taken into account because sulfonulureas may lead to potentiation of anticoagulation during concomitant treatment. Adjustment of the anticoagulant dosage may be necessary.

Intolerance to alcohol (disulfiram-like reaction: flushing, sensation of warmth, giddiness, nausea and occasionally tachycardia) may occur in patients treated with sulfonylurea. This reaction can be prevented by avoiding the use of alcohol. Alcohol increases the hypoglycaemic reaction (by inhibiting compensatory reactions) that can lead to the onset of hypoglycaemic coma. Avoid alcohol or medicines containing alcohol.

Drug-Herb Interactions

St. John's Wort

Pharmacodynamic interactions between gliclazide and the herbal remedy St. John's Wort may occur and may lead to hyperglycemia or loss of blood glucose control.

ADVERSE REACTIONS

In clinical trials involving about 2000 patients treated with gliclazide, the overall incidence of adverse reaction was 10.5%; this necessitated the discontinuation of therapy in 1.2% of patients.

Adverse Drug Reaction Overview

The most frequently reported adverse drug reactions during long-term studies and post-market experience are hypoglycaemia (see WARNINGS AND PRECAUTIONS) and gastrointestinal disturbances (including abdominal pain, nausea, vomiting, dyspepsia, diarrhea, constipation).

Hypoglycemia (see PRECAUTIONS):

Weakness, nervousness, shakiness and paresthesia have been reported. Severe hypoglycemia which mimics acute CNS disorders may occur. Hepatic and/or renal impairment, malnutrition, debility, advanced age, alcoholism, adrenal or pituitary insufficiency may be predisposing factors.

Gastro-intestinal reactions:

Nausea, vomiting, diarrhea, epigastric fullness and gastric irritation can be observed. These reactions are generally dose-related and may disappear when the dose is reduced.

Hepatobiliary reactions:

With sulfonylureas cases were also observed of elevated liver enzyme levels (AST, ALT, alkaline phosphatase) and even impairment of liver function with cholestasis and jaundice and hepatitis which regressed after withdrawal of the sulfonylurea or led to life-threatening liver

failure in isolated cases. Rare cases of jaundice have been reported. Discontinue treatment if cholestatic jaundice appears.

Dermatological reactions:

Allergic reactions such as pruritus, erythema, urticaria and morbiliform or maculopapular rash have been reported. These reactions may persist during treatment, which must then be interrupted. Cases of cutanea porphyria tarda and of photosensitivity have also been described with sulfonylurea drugs.

Hematological reactions:

As with all hypoglycemic sulfonylurea drugs, a few rare cases have been reported of leukopenia, erythrocytopenia agranulocytosis, thrombocytopenia, haemolytic anemia, pancytopenia and allergic vasculitis.

Metabolic reactions:

Cases of hepatic porphyria and disulfiram-like reactions have been described with sulfonylurea drugs. Clinical experience to date has shown that gliclazide has a low incidence of disulfiram type reactions.

Cardiovascular:

Arteritis, cardiac failure, cerebrovascular disorder, coronary artery disorder, epistaxis, hypotension, myocardial infarction, oedema legs, palpitation, tachycardia, thrombophlebitis, vein disorder.

Endocrine reactions:

A decrease in the uptake of radioactive iodine by the thyroid gland has been reported with other sulfonylurea drugs. This has not been shown with gliclazide during a study involving 15 patients.

Laboratory tests:

The pattern of laboratory tests abnormalities observed with gliclazide was similar to that for other sulfonylureas. Occasional mild to moderate elevations of SGOT, LDH and creatinine and decrease in natremia have been observed. These abnormalities frequently encountered with treated or untreated diabetic patients are rarely associated with clinical symptoms and generally not considered to be drug related.

Post-Market Adverse Drug Reactions:

In post-marketing experience with gliclazide, the most frequently reported adverse drug reaction is hypoglycaemia.

The most serious adverse drug reactions reported with gliclazide are hypoglycaemic coma, pancytopenia, thrombocytopenia, hepatitis, cholestatic jaundice, pyrexia, and skin reactions (pruritus and rash).

Gastrointestinal disturbances, including abdominal pain, nausea, vomiting, dyspepsia, diarrhea and constipation have been reported.

Skin and subcutaneous tissue disorders, rash, pruritus, urticaria, angioedema, erythema, maculopapular rashes, bullous reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis) and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported.

The following adverse events have also been observed with gliclazide: cases of erythrocytopenia, agranulocytosis, haemolytic anemia, allergic vasculitis, hyponatremia, and elevated liver enzyme levels (AST, ALT, alkaline phosphatase); isolated cases of impairment of liver function with cholestasis and jaundice which can regress after withdrawal of the drug or may lead to life-threatening liver failure. Discontinue treatment if cholestatic jaundice appears.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre Immediately.

Symptoms:

Overdosage with sulfonylureas may result in hypoglycemia but it should be noted that the dosage which causes such hypoglycemia varies widely and may be within the accepted therapeutic range in sensitive individuals.

The manifestations of hypoglycemia include sweating, flushing or pallor, numbness, chilliness, hunger, trembling, headache, dizziness, increased pulse rate, palpitations, increased blood pressure and apprehensiveness in mild cases. In more severe cases, coma appears.

However, symptoms of hypoglycemia are not necessarily as typical as those described above and sulfonylureas may cause insidious development of symptoms mimicking cerebrovascular insufficiency.

Treatment:

Discontinue medication and treat hypoglycemia by giving dextrose promptly and in sufficient quantity.

Some sulfonylurea-induced hypoglycemias may be refractory to treatment and susceptible to relapse especially in elderly or malnourished patients. Continuous dextrose infusions for hours or days have been necessary.

Strict monitoring should be continued until the doctor is sure that the patient is out of danger.

Severe hypoglycaemic reactions, with coma, convulsions or other neurological disorders are possible and must be treated as a medical emergency, requiring immediate hospitalisation. If hypoglycaemic coma is diagnosed or suspected, the patient should be given a rapid I.V. injection of 50 mL of concentrated glucose solution (20 to 30 %). This should be followed by continuous infusion of a more dilute glucose solution (10 %) at a rate that will maintain blood glucose levels above 1 g/L. Patients should be monitored closely and, depending on the patient's condition after this time, the doctor will decide if further monitoring is necessary.

Dialysis is of no benefit to patients due to the strong binding of gliclazide to proteins.

DOSAGE AND ADMINISTRATION

Determination of the proper dosage for MYLAN-GLICLAZIDE for each patient should be made on the basis of frequent determinations of blood glucose during dose titration and throughout maintenance.

The recommended daily dosage of MYLAN-GLICLAZIDE (gliclazide) is 80 to 320 mg (1 to 4 tablets). Dosage of 160 mg and above should be divided into two equal parts for twice a day administration. MYLAN-GLICLAZIDE should be taken preferentially with meals.

The recommended starting dose of MYLAN-GLICLAZIDE (gliclazide) is 2 tablets per day (160 mg) taken as one tablet twice a day with meals. The total daily dose should not exceed 320 milligrams.

Patients with renal or hepatic impairment may require dosage reduction (See PRECAUTIONS, Hypoglycemic reactions).

In patients where on initial trial the maximal recommended dose fails to lower blood glucose adequately, the drug should be discontinued. During the course of therapy a loss of effectiveness may occur.

It is advisable to ascertain the contribution of the drug in control of the blood glucose by discontinuing the medication semi-annually or at least annually with careful monitoring of the patient. If the need for the drug is not evident, the drug should not be resumed. In some diabetic subjects, short-term administration periods of the drug may be sufficient during periods of transient loss of blood sugar controls.

Patients receiving insulin:

Maturity onset diabetics with no ketoacidosis or history of metabolic decompensation and whose insulin requirements are less than 40 units per day may be considered for MYLAN-GLICLAZIDE (gliclazide) therapy after cessation of insulin. If a change from insulin to MYLAN-GLICLAZIDE (gliclazide) is contemplated in such a patient, discontinue insulin for a period of 2 or 3 days to determine whether any therapy other than dietary regulation and exercise is needed. During this insulin free interval, test the patient's urine at least 3 times daily for glucose and ketone bodies and monitor the results carefully. The appearance of significant ketonuria accompanied by glucosuria within 12 to 24 hours after the withdrawal of insulin, strongly suggests that the patient is ketosis prone, and precludes the change from insulin to sulfonylurea therapy.

HOW SUPPLIED

MYLAN-GLICLAZIDE (gliclazide) is available as 80 mg white, flat bevelled edged, round tablet with "GZ" over "80" on one side and quadrisect scored on the other side.

MYLAN-GLICLAZIDE is available in blister packs containing 60 tablets and white opaque HDPE bottles of 100 and 500 tablets.

INFORMATION TO THE PATIENT

Full prescribing information is available to the physicians and pharmacists.

MYLAN-GLICLAZIDE is available only with your physician's prescription.

MYLAN-GLICLAZIDE is used to lower blood glucose level in adult patients with type 2 diabetes mellitus in addition to proper diet, exercise and weight reduction.

MYLAN-GLICLAZIDE belongs to the family of hypoglycemic (antidiabetic) drugs and part of a sub family of medicines called sulfonylureas. It helps improving insulin secretion in the body.

Before you begin treatment with this medicine, you and your doctor should talk about the good medicine will do as well as the risks of using it. You should also find out about other possible ways to control your diabetes such as diet alone or by diet plus insulin.

Use only as specifically directed. Do not alter the dosage unless ordered to do so by your physician.

Before using this medicine

MYLAN-GLICLAZIDE may cause low blood sugar (hypoglycemia). You should ask your doctor, pharmacist or diabetes educator about symptoms of low blood sugar and what to do if you experience these symptoms. You should also test your blood sugar as instructed by your doctor.

Before you use MYLAN-GLICLAZIDE talk to your doctor or pharmacist if:

- you have or have had liver problems
- you have or have had kidney problems
- you are pregnant or planning to get pregnant
- you are breast-feeding
- you have a blood disease called G6PD-deficiency anemia.

MYLAN-GLICLAZIDE is not recommended for use in children under 18 years of age.

Driving and Operating Machinery:

Alertness and reactions may be impaired due to low blood sugar (hypoglycemia), especially at beginning of the treatment. This may affect your ability to drive or to operate machinery.

Proper use of this medicine

Follow carefully the special meal plan your physician gave you. This is the most important part of controlling your condition and is necessary if the medicine is to work properly.

Take MYLAN-GLICLAZIDE with a meal as directed by your physician. Do not take more nor less of it than your doctor ordered, and take it at the same time each day. If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

MYLAN-GLICLAZIDE is contraindicated (must not be taken) in the following conditions:

- Allergy or hypersensitivity to gliclazide, other sulphonylureas, sulphonamides or to any of the excipients of this product.
- Unstable and/or insulin-dependent diabetes mellitus (type I diabetes), particularly juvenile diabetes, diabetes ketoacidosis, diabetes pre-coma and coma.
- Stressful conditions such as serious infection, trauma or surgery.
- Severe liver impairment.
- Severe kidney impairment.
- Treatment with miconazole.
- Pregnancy and/or breast-feeding.

The safety of MYLAN-GLICLAZIDE in adolescents and children has not been established.

MYLAN-GLICLAZIDE is prescribed for your specific medical problem and for your own use only. Do not give to other people.

Keep all medicines out of the reach of children.

Precautions while using this medicine

Your physician should check your progress at regular visits, especially during the first few weeks that you take this medicine. Please keep your appointments.

Test for sugar in your blood or urine as directed by your physician. This is a convenient way to make sure your diabetes is being controlled and provides an early warning when it is not.

Do not take any other medicine, unless prescribed or approved by your doctor. If you require medical assistance, inform the medical practitioner that you are taking MYLAN-GLICLAZIDE.

Drugs that may interact with MYLAN-GLICLAZIDE are:

- Other antidiabetic agents, long-acting sulfonamides, tuberculostatics, clarithromycin, NSAIDs, fibrates, monoamine oxidase inhibitors, salicylates, probenecid, beta-blockers, azole antifungal agents (oral and parenteral preparations), H₂-receptor antagonists and angiotensin converting enzyme inhibitors, anticoagulants, barbiturates and fluoroquinolones . Certain drugs tend to induce hyperglycemia and may lead to loss of blood sugar control. These include diuretics (thiazides, furosemide), corticosteroids, oral contraceptives (estrogen plus progestogen), chlorpromazine, ritodrine, salbutamol, terbutaline, danazol and nicotinic acid in pharmacologic doses. Low blood sugar and high

blood sugar can occur when a medicine belonging to a class of antibiotics called fluoroquinolones is taken at the same time as MYLAN-GLICLAZIDE, especially if you are elderly. If you are taking these medications together, your doctor will remind you of the importance of monitoring your blood glucose.

Herbs that may interact with MYLAN-GLICLAZIDE are:

- Saint John's Wort preparations tend to cause high blood sugar and may lead to loss of blood sugar control.

Serious Skin Reactions (DRESS, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, hypersensitivity Syndrome): any combination of red itchy rash with blisters and peeling of the skin and /or of the lips, eyes, mouth, nasal passages or genitals have been reported in patients taking gliclazide. It often goes with fever, chills, headache, cough, body aches or joint pain. You may have less or dark urine, yellow skin or eyes. If you suspect these, you should stop taking the drug and talk with your doctor or pharmacist.

Avoid drinking alcoholic beverages and taking medicines containing alcohol while you are taking MYLAN-GLICLAZIDE as it can lead to drop in blood sugar (hypoglycemia).

Inform your physician about any illness which may develop during your treatment with MYLAN-GLICLAZIDE and about any new prescribed or non-prescribed medication you may be taking.

Side effects of this medicine

Along with their needed effects, oral antidiabetes medicines may cause some unwanted effects. The more frequently reported side effects during clinical trials with gliclazide were hypoglycemia (low blood sugar) and indigestion or stomach upsets.

You should know that the usual signs of low blood sugar level (hypoglycemia) are: anxious feeling, drowsiness, chills, cold sweats, confusion, cool pale skin, difficulty in concentration, excessive hunger, fast heartbeat, headache, nausea, nervousness, shakiness, unsteady walk, unusual tiredness or weakness. If you recognize by some of these signs of the drop in blood sugar, immediately eat or drink something containing sugar and notify your doctor without delay. Good sources of sugar are: orange juice, corn syrup, honey, or sugar cubes or table sugar (dissolved in water).

In addition, some uncommon serious side effects/symptoms may happen and you should stop taking the drug and talk with your doctor or pharmacist in all cases: unexplained fever chills or sore throat; yellowing of skin or eyes, dark-coloured urine or light-coloured bowel movements (e.g. jaundice) which in most cases disappeared after withdrawal of the drug, but may lead to life-threatening liver failure in isolated cases; skin rash, redness, itching or hives; oedema, swelling of the legs or unexpected weight gain; chest pain or pressure, and/or shortness of breath.

Very rare cases of the following have been reported: blood abnormalities with symptoms of sore throat, fever, mouth sore, unusual bleeding or bruising, low level of red blood cells (anemia); allergic inflammation of blood vessels (vasculitis); low sodium level in blood combined with symptoms of tiredness, weakness and confusion (hyponatraemia); rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty (angioedema); widespread blistering or peeling of the skin.

Serious Skin Reactions (DRESS, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, hypersensitivity Syndrome): any combination of red itchy rash with blisters and peeling of the skin and /or of the lips, eyes, mouth, nasal passages or genitals have been reported in patients taking gliclazide. It often goes with fever, chills, headache, cough, body aches or joint pain. You may have less or dark urine, yellow skin or eyes. If you suspect these, you should stop taking the drug and talk with your doctor or pharmacist.

Additional information on MYLAN-GLICLAZIDE may be obtained from your physician or pharmacist.

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at [MedEffect](http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php); (<http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php>)
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 1908CE
Ottawa, ON
K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php). (<http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php>)

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.


PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Gliclazide

Chemical Name: 1-(3-azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea

Structural Formula:



Molecular Formula: C₁₅H₂₁N₃O₃S

Molecular Weight: 323.41 g/mol

Description: Gliclazide is a white, crystalline, odourless powder.

Solubility: Practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in acetone, slightly soluble in ethanol (96%)

PKa: 5.8

Melting point: 165 to 170 °C

Composition

Non-medicinal ingredients: Lactose, Magnesium Stearate, Microcrystalline Cellulose, Povidone, Sodium Starch Glycollate and Talc.

Stability and Storage Recommendations

Store at room temperature between 15 to 30°C.

PHARMACOLOGY

see Published Review by HOLMES et al. (Drugs 1984)

HUMAN PHARMACOLOGY

1. Pharmacokinetics and metabolism

COMPARATIVE BIOAVAILABILITY STUDIES

A comparative, bioavailability study was conducted to compare the rate and extent of absorption of MYLAN-GLICLAZIDE 80 mg tablets against the Canadian Reference Product, Diamicon® (Servier Canada Inc.) 80 mg tablets. The study was a Three-way, Single-Dose, Fasting Bioavailability Study of Gliclazide 80 mg Tablets in Normal, Healthy Male Volunteers (N=11). The pharmacokinetic data calculated for MYLAN-GLICLAZIDE and Diamicon® (Servier Canada Inc.) are presented below:

Gliclazide (1 x 80 mg) From measured data Geometric Mean Arithmetic Mean (CV%)				
Parameter	Geometric Mean Arithmetic Mean		Ratio of Means (%)	90% C.I.
	Mean (C.V)			
	Mylan-Gliclazide (A)	**Diamicon® (B)		
AUC (0-t hrs.) (ng.hr/mL)	45593.94 49356.82 (40.18)	43682.30 46356.29 (39.77)	104.38	98.16 – 110.98
AUC (0-infinity) (ng.hr/mL)	52445.70 58551.52 (50.09)	50297.43 55376.52 (49.17)	104.27	96.80 – 113.32
C _{max} (ng/mL)	2607.34 2703.58 (25.96)	3065.36 3226.45 (32.55)	85.06	73.10 – 98.97
T _{max} (hours)*	8.75 (29.71)	8.17 (33.78)	--	--
t _{1/2} (hours)*	14.86 (32.70)	14.89 (42.38)	--	--
K _{el} (hour ⁻¹)*	0.050 (26.0)	0.053 (35.85)	--	--

*These are arithmetic means (CV%).

**Diamicon® (gliclazide) 80 mg tablets (Servier Canada Inc.) were purchased in Canada

Absorption: Gliclazide is extensively absorbed from the gastrointestinal tract. Following oral administration of 3 mg/kg of gliclazide to four healthy subjects, the peak plasma levels (mean 5.0 µg/ml) were achieved between 4 to 6 hours. The absorption half-life in man is 1.3 hours.

Distribution: The mean apparent volume of distribution in 4 healthy subjects was 20 to 40% of bodyweight.

Protein binding: Using equilibrium dialysis, it was shown that the majority of the drug is protein bound. At a plasma concentration of about 8 µm/ml, 94.2% of the drug was protein bound and 5.8% was free.

Metabolism: Although more than 90% of unchanged gliclazide is found in plasma following administration, this is intensively metabolized with little of the unchanged compound (< 1%) found in urine. Five principal metabolites have been found in urine, essentially oxidized and hydroxylated derivatives, the majority of which undergo glucuroconjugation.

Excretion: Gliclazide is essentially eliminated via the urine: 60 to 70% as against 10 to 20% via faeces.

Half life: The mean elimination half-life is 10.4 h.

2. Pharmacodynamics

Gliclazide acts primarily by enhancing the release of endogenous insulin. Residual function of beta-cells is therefore necessary for its action. Clinical studies demonstrate that the sulphonylureas are ineffective in completely pancreatectomized patients and in juvenile onset diabetic subjects. The mechanism of action is not fully understood. Sulphonylureas including gliclazide cause degranulation of the pancreatic beta-cells; a phenomenon associated with increased rate of insulin secretion.

Extrapancreatic effects of sulphonylureas have been reported and certain of these may potentiate the effects of secreted insulin. These effects include reduction in hepatic uptake of endogenous insulin and increased sensitivity of peripheral tissues to insulin. Sulphonylurea agents may stimulate hyperplasia of the beta-cells.

At normal therapeutic doses gliclazide has been shown in man to reduce platelet adhesiveness and aggregation. When these are close to normal at the inclusion time, no significant difference is observed.

ANIMAL PHARMACOLOGY

1. Pharmacokinetics and metabolism

This has been studied in four animal species (monkey, dog, rabbit and rat) and in man after single or repeated administration of gliclazide. The principal characteristics are shown in the table below.

BLOOD KINETICS OF GLICLAZIDE (PO)
IN DIFFERENT SPECIES
(single doses)

SPECIES	NUMBER OF SUBJECTS DOSES	ABSORPTION T 1/2(h)	PLASMA PEAK (h)	VOLUME OF DISTRIBUTION (% body weight)	PLASMA HALF-TIME (h)
Man	4 3 mg/kg	1.3 (1)	4-6 (1)	36.3 (1) -	10.4 (1) -
Monkey	4 3 and 50 mg/kg	0.3 (1)	1-2 (1)	24.4 (1) 108 (4)	2.9 (1) 6.2 (4)
Beagle	3 3 and 50 mg/kg	0.7 (1)	2-6 (1)	21..3 (1) 22 (4)	10.7 (1) 9.9 (4)
Rabbit	5 10 and 25 mg/kg	0.7 (2)	3 (2)	30.8 (2) 51.8 (3)	3.9 (2) 5.9 (3)
Rat	5 10 mg/kg	0.5 (2)	1 (2)	53.8 (2) -	2.5 (2) -


(1) = 3 mg/kg PO (3) = 25 mg/kg PO
(2) = 10 mg/kg PO (4) = 50 mg/kg PO

Gliclazide is rapidly absorbed in all species, with a plasma peak observed between 1 and 6 hours. More than 90% of gliclazide is found unchanged in the plasma. Elimination from plasma is monophasic with inter-species variations concerning half-life (2.5 hours in the rat, 10.4 hours in man).

Excretion is similar in all species with 60 to 70% of the dose found in urine and 10 to 20% in faeces.

The drug is intensively metabolized into at least 5 metabolites and only small amounts of unchanged compound are excreted in the urine.

The principal metabolic pathways of gliclazide may be summarized as follows:



VALUES ARE APPROXIMATE % OF DOSE EXCRETED INTO 0-24 HOUR URINE

2. Hypoglycemic activity

The hypoglycemic action of gliclazide has been observed in the rat, rabbit, guinea-pig and dog following intravenous or oral administration. The degree and duration of these effects are dose dependent.

Comparison of ED 30 shows that gliclazide is 9 times more active than tolbutamine in the rabbit and 25 times more active in the rat. The duration of action of gliclazide is also greater than that of tolbutamide.

Gliclazide stimulates the insulin secretion and particularly restores the early peak in the isolated perfused pancreas of diabetic rats.

This insulinotropic action is related to the transfer of calcium into the pancreatic cell. Gliclazide is not involved in the biosynthesis of insulin induced by glucose but modifies the distribution of calcium in isolated rat pancreas cells.

At the extrapancreatic level, gliclazide potentialises the action of insulin on the glucose intracellular transfer and influences its oxydation on an isolated adipocyte model when insulin is present in the medium.

3. Haemovascular activity

Gliclazide delays the development of the mural thrombus formed after electrical lesion of the vascular endothelium in the rat and increases its disaggregation speed.

In dog, gliclazide prevents the formation of capillary ADP-induced platelet aggregates at the retinal level.

These properties can be explained by its action on

- 1) The platelet behaviour: reduction of the platelet adhesiveness in the diabetic rabbit of platelet aggregation induced by ADP or by collagen in the rabbit.
- 2) The prostaglandin equilibrium: inhibition of the acid arachidonic release and in vitro thomboxan synthesis and increase of the PGI₂ production.
- 3) The parietal fibrinolysis: increase of the release of the parietal plasminogen activator (t.PA). This activator, of an endothelial origin, acts on the plasmin which is the enzyme degrading the fibrin.

4. Other actions

Gliclazide has no action on the central nervous system, autonomic nervous system nor respiratory, gastro-intestinal and cardiovascular systems.

TOXICOLOGY

see Published Review by HOLMES et al (DRUGS 1984)

1. Acute toxicity

Species	Mean Weight	Number of animals per lot	DL 50 (mg/kg)
Mouse CD-SPF	25 g	10 M 10 F	> 3 000
Mouse ICR-HAN	20 g	10 M 10 F	> 4 000
Rat SD-SPF	250 g	10 M	3733 <div style="display: inline-block; vertical-align: middle;"> <div style="display: inline-block; vertical-align: middle;">5200</div> </div> <div style="display: inline-block; vertical-align: middle;"> <div style="display: inline-block; vertical-align: middle;">2679</div> </div>

Species	Mean Weight	Number of animals per lot	DL 50 (mg/kg)	
		10 F	3407 $\left\{ \begin{array}{l} 5467 \\ 2123 \end{array} \right.$	
Rat CFY	110 g	6 M 6 F	> 4 000	
Tricolor Guinea Pig	240 g		48 hours	10 days
		4 M	1732 $\left\{ \begin{array}{l} 1999 \\ 1501 \end{array} \right.$	1599 $\left\{ \begin{array}{l} 2016 \\ 1269 \end{array} \right.$
		4 F	2244 $\left\{ \begin{array}{l} 2509 \\ 1944 \end{array} \right.$	2068 $\left\{ \begin{array}{l} 2553 \\ 1675 \end{array} \right.$
Beagle dog	7 kg	3 M 3 F	> 3000	

The LD 50 is greater than 3000 mg/kg in the mouse, rat and dog (i.e. 750 times the therapeutic dose) and than 2000 mg/kg in the guinea-pig (i.e. 500 times the therapeutic dose).

Symptomatology is essentially linked to the hypoglycemic effect of the drug.

2.Sub-chronic toxicity

- Maximum tolerated dose:

In the dog, this dose is between 150 and 200 mg/kg by daily administration.

- Four-week oral toxicity study in the Beagle dog:

Groups of 4 Beagle dogs (2 males, 2 females), were treated for 30 days with 0, 15, 30, 45 or 90 mg/kg/day.

At the dose of 90 mg/kg, 2 animals died as a result of prolonged hypoglycemic coma following 2 weeks of treatment.

All others showed normal behaviour, with the exception of an increase in the weight of the liver. No evidence was found of any change in biochemical (apart from the fall in blood glucose), haematological and histopathological parameters.

- Two-month oral toxicity study in the guinea-pig:

Groups of 10 guinea-pigs (5 males, 5 females), were treated 6 days out of 7 for 2 months with 0, 25, 50 or 100 mg/kg/day.

Only male animals in the 50 mg/kg group showed delayed weight gain.

All others had normal biochemical, haematological and hispathological results.

3. Chronic toxicity

- Six-month study in the Sprague-Dawley rat:

Groups of 20 rats (10 males, 10 females) weighing 300 g, were treated for 6 days out of 7 for 6 months with 0, 25, 100 or 200 mg/kg/day.

Seven deaths occurred as a result of technical problems.

All other animals showed normal behaviour and haematological results. From a biochemical standpoint, blood urea decreased significantly in the male rats as did blood glucose in the males of the 100 mg/kg/day group.

Histological examination showed an increase in the weight of the liver and kidneys in male animals, not accompanied by any histological lesion.

A six-month rat study carried out in Japan with higher doses (50, 100, 200, 400 and 800 mg/kg) indicates a possible higher sensibility in the female to the product: slight increases in liver enzymes together with slight decreases in erythrocytes counts, hematocrit values and haemoglobin concentrations at doses of 200 mg/kg and higher.

- Six-month study in the Beagle dog:

Groups of 6 dogs (3 males, 3 females) were treated daily for 6 months with 15 or 30 mg/kg of gliclazide or 30 mg/kg of gliclazide or 50 mg/kg of tolbutamide.

From a clinical standpoint:

- 3 deaths (one at 15 mg/kg, two at 30 mg/kg) in the gliclazide group as a result of hypoglycemic coma.
- 1 convulsion, 4 cases of severe gastro-intestinal disturbances in the tolbutamide group.
- Weight changes and food consumption were similar with both drugs.

From a laboratory standpoint:

- 40% fall in blood glucose in animals treated with gliclazide.
- Signs of hepatotoxicity in the tolbutamide group.

From a histological standpoint:

- Increase in weight of the liver in the 3 deaths of the gliclazide group.
- Increase in the weight of the liver and lesions of toxic hepatitis in 5 animals out of 6 of the tolbutamide group.

- Twelve-month oral toxicity study in the Beagle dog:

Groups of 8 dogs (4 males, 4 females) were treated for 12 months with 0, 12 or 24 mg/kg/day of gliclazide.

Four animals in each group were sacrificed after 90 days.

- there were no deaths;
- no evidence of any modification in behaviour and body weight;
- significant fall in blood glucose;
- fluctuation in certain parameters (liver enzymes, lipid profile, creatinine);
- at autopsy: swelling of the renal and hepatic parenchyma and at the highest dose a slight increase in the weight of the thyroid and slight decrease in the weight of the pituitary gland.

- Twelve-month oral toxicity study in the rhesus monkey:

Groups of 8 rhesus monkeys (4 males, 4 females) were treated daily for 12 months with 0, 20, 60 or 180 mg/kg of gliclazide.

- no evidence was found of any modification in weight gain nor food consumption;
- significant fall in blood glucose;
- irregular rise in some liver enzymes in some animals;
- no abnormality by histopathological examination.

TERATOGENICITY

Teratogenicity studies have been carried out in three species: mouse, rat and rabbit.

- In the CD/SPF mouse (group of 30 females), administration of gliclazide at doses of 0, 50, 200 and 500 mg/kg/day starting from mating and throughout gestation did not modify fertilization and abortion rates and had no apparent teratogenic effect.
- In the CFY-SPF rat (groups of 20 females), administration of gliclazide at doses of 0, 50, 100 and 200 mg/kg/day from the 6th to the 15th day of gestation did not show any embryotoxic effect.
- In the SD/SPF rat (groups of 60 females), administration of gliclazide at the doses of 0, 15, 60, 120, 240 and 480 mg/kg/day throughout gestation had no effect on fertilization, gestation, mean number of foetuses or incidence of foetal abnormalities. The number of offspring surviving at 48 hours was decreased in the 15, 60, 120 and 480 mg/kg groups. No other abnormality was seen.
- In the common rabbit (group of 15 females), administration of gliclazide at doses of 0, 10, 25 and 50 mg/kg/day from the 6th to the 18th day of gestation had no effect on the number of foetal resorptions, percentage of abortion nor the mean number of foetuses per litter.
- In the New Zealand rabbit (group of 6 females), administration of gliclazide at doses of 0, 50, 75, 100 and 200 mg/kg/day for 13 days followed by an observation period of 8 days, was associated with maternotoxicity and embryotoxicity in the form of gastrointestinal and renal lesions accompanied by anorexia and weight loss. However, there was no evidence of any teratogenic effect.

FERTILITY AND REPRODUCTION

In the SD rat, groups of 40 females and of 20 males were treated for 8 and 70 days respectively before mating and until weaning in the females, and until 15 days after littering in the males, with gliclazide at doses of 0, 10, 50 and 200 mg/kg/day.

There was no evidence of any change in fertilization or abortion rates. Foetal resorption, placental haemorrhage and foetal atrophy rates were unaffected. The genital tract of treated parents showed no abnormality imputable to treatment.

No embryotoxic effect was seen on foetuses of females sacrificed before littering.

In females in which gestation was allowed to run to term, a significant decrease in the viability of offspring was seen at 48 hours.

No abnormality was seen during the study of fertility and reproduction in first generation offspring born of treated animals.

MUTAGENICITY

The mutagenic potential of gliclazide has been sought using five mutagenesis tests, i.e.:

- 2 gene mutation tests (Ames test),
- 1 in vitro chromosomal aberration test (human lymphocyte test),
- 2 in vivo chromosomal tests (micronucleus test).

GENE MUTATION TESTS

1st Ames test

In this test, gliclazide was used in the presence of 5 strains of Salmonella typhimurium (TA 1535/1537/1538/98/100) at the doses of 0, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 3, 5 and 8 mg/petri dish, with and without metabolic activators. Positive controls were used for each strain with and without metabolic activators.

The qualitative test showed no mutagenic effect. The quantitative test at doses of 0.005 mg to 8 mg/dish showed no significant increase in the number of revertants.

Thus no mutagenic effect was seen under the experimental conditions adopted.

2nd Ames test

This test used 7 strains of Salmonella typhimurium (TA 97/98/100/102/1535/1537/1538) at the doses of 0, 0.05, 0.1, 0.5, 1, 3, 5 and 8 mg of gliclazide per petri dish, in the presence and absence of metabolic activator. Positive controls were used for each strain, with and without metabolic activators.

No mutagenic effect was seen in the qualitative test. No mutagenic activity was detected in the quantitative test under the experimental conditions described.

IN VITRO CHROMOSOMAL ABBERATION TEST

Possible clastogenic potential action of gliclazide on activated lymphocytes in culture was studied by the human lymphocyte test with and without metabolic activators. Maximum tolerated doses determined in the preliminary toxicity test were 0.033 mg/ml with metabolic activators and 0.1 mg/ml without metabolic activator.

Gliclazide was used at the following concentrations:

- 0, 0.003, 0.01 and 0.033 mg/ml with metabolic activators;
- 0, 0.01, 0.033 and 0.1 mg/ml without metabolic activator.

Cyclophosphamide (0.02 mg/ml) and bleomycin (0.250 mg/ml) were used as positive controls with and without metabolic activators. Gliclazide was not found to have any clastogenic activity under the experimental conditions described.

IN VIVO CHROMOSOMAL ABERRATION TEST

MICRONUCLEUS TEST

1st test

The test used three groups of 10 OF1 mice: 1 negative control, 1 gliclazide high dose (2 g/kg x 2), 1 gliclazide low dose (1 g/kg x 2) and one group of 5 positive control mice given cyclophosphamide (50 mg/kg x 2).

No evidence was found of any significant variation in the number of erythrocyte micronuclei. Gliclazide was not associated with any mutagenic action detectable by the micronucleus test.

2nd test

The test used SPF Swiss mice as follows:

- 24 mice for the preliminary toxicology test which determined the maximum administrable dose as 3 g/kg;
- 108 mice in the phase 1 genetic toxicology test with study of effect/time relationship at the maximum administrable dose (MAD) (sacrifice of animals at times 24, 48 and 72 hours);
- 60 mice in the phase 2 genetic toxicology test with study of the dose/effect relationship at the time defined in phase 1 (t = 24 h) and using the following doses: 0, 750 (MAD/4), 1500 (MAD/2) and 3000 mg/kg (MAD).

Cyclophosphamide 50 mg/kg was used as positive control.

Gliclazide was found to be free of any clastogenic activity under the experimental conditions adopted in this trial involving oral administration in the Swiss mouse.

CARCINOGENICITY STUDIES

Specific carcinogenicity studies have not been performed, the following safety data are now available:

- Gliclazide belongs to the chemical class of the phenylsulfonyleurea which did not demonstrate any mutagenic or carcinogenic potential. Its metabolic pathway is consistent with the general metabolic pathway of the class.
- Gliclazide was not associated with any mutagenic action in the numerous studies performed.
- Long term toxicity studies did not reveal any evidence of carcinogenicity.

- Gliclazide has been studied in several thousands of patients during clinical trials and is marketed for numerous years all over the world and in particular in Europe and Japan without any suspicion of carcinogenicity.

REFERENCES

1. Baba S et coll: Double-blind randomized control study with gliclazide *Clin Eva* 1983; **11**(1):51-94
2. Campbell DB, Adriaenssens PI, Hopkins YW, Gordon B, Williams JRB: Pharmacokinetics and metabolism of gliclazide. A review *Royal Soc Med Int Congr Symp* 1980; **20**:71-82
3. Campbell DB, Forette B, Rolland A, Hopkins Y, Gordon BH: Gliclazide pharmacokinetics in the elderly *Excerpta Medica* 1982; **577**:8
4. Chan TK, Ckan V, Teng CS, Yeung RTT: Progression of diabetic background retinopathy: the effect of gliclazide compared to glibenclamide and the relationship to haemobiological changes *Excerpta Medica* 1982; **577**:7
5. Chan TK, Chan V, Teng CS, Yeung RTT: Effets du gliclazide et du glibenclamide sur les fonctions plaquettaires, la fibrinolyse et l'équilibre glycémique chez des diabétiques présentant une rétinopathie *Sem Hop Paris* 1982; **58**(19):1197-1200
6. Chiasson JL, Bergman RN, Verdy M, Hamet P, De Lean A: Study on effect of gliclazide on secretion and action of insulin in normal and type II diabetic humans *Bull Int Diabete Fed* 1987; **32**(1): 9-11
7. Desnoyers P, Saint-Dizier D: The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties *Arzneimittelforsch* 1972; **22**:1691-1695
8. Duhault J, Lebon F: Protective activity of S 1702 on the microvascular system in normal and diabetic rats *Arzneimittelforsch* 1972; **22**:1686-1690
9. Duhault J, Regnault F, Boulanger M, Tisserand F: Prevention of experimental obstructions in the retinal microcirculation *Ophthalmologica* 1975; **170**:345-352
10. Futijani B, Maeda J, Tsuboi T et coll: Effect of gliclazide on prostaglandin I₂ formation in normal streptozotocin-induced diabetic animals *Jpn J Pharmacol* 1983; **33**:965-970
11. Gamstedt A, Fagerberg SE: Long-term metabolic effects of gliclazide in NIDDM *FADL Publish* 1987; 16-19
12. Golay A, Broquet C, Chabot V, Studer S, Felber JP: Effets métaboliques du gliclazide chez le diabétique de type II. Étude par calorimétrie indirecte *Schweiz Med Wochenschr* 1984; **114**(8):261-264
13. Harrower A: Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas *Curr Med Res Opin* 1985; **9**:676-680

14. Hoich RI, Ng FM: Insulin-potentiating action of gliclazide (Diamicon) *Pharmacol Res Commun* 1986; **18**(5):419-430
15. Holmes B et coll: Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus *Drugs* 1984; **27**:301-327
16. Ings RMJ, Campbell B, Gordon BH, Beaufile M, Meyrier A, Jones R: The effect of renal disease on the pharmacokinetics of gliclazide in diabetic patients *Br J Clin Pharmacol* 1986; **21**(5):572-573
17. Jerums G et coll: Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study *Diabetes Res Clin Pract* 1987; **3**:71-80
18. Kilo C, Dudley J, Kalb E: Evaluation of safety and efficacy of gliclazide in non-insulin-dependent diabetic patients *Bull Int Diabete Fed* 1987; **32**(1):27-29
19. Kosaka K et coll: Clinical comparative study on the therapeutic effects of oral hypoglycaemic agents in patients with diabetic retinopathy *J Jpn Diab Soc* 1983; **26**(5):531-540
20. Kuwashima J et coll: Inhibition by gliclazide of platelet adhesiveness and aggregation in the rabbit made diabetic by alloxan *Yakugaku Zasshi* 1979; **99**(1):50-64
21. Larkins R, Jerums G, Taft JL, Godfrey H, Smith IL, Martin TJ: Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study *Diabetes Res Clin Pract* 1988; **4**:81-87
22. Malaisse WJ, Couturier E, Valverde I: The insulinotropic action of gliclazide: possible mode of action *Royal Soc Med Int Congr Symp* 1980; **20**:37-42
23. Marchand D et coll: The hypoglycemic effect of a sulfonylurea (gliclazide) in moderate type II diabetes and glucose intolerance is not accompanied by changes in insulin action and insulin binding to erythrocytes *Molecular Physiology* 1983; **4**:83-93
24. Masbernard A, Portal A: Le vrai problème du diabète. Essai du gliclazide, molécule originale à propriétés métaboliques et vasculaires *Sem Hop Paris Ther* 1972; **48**(9):569-573
25. Matsuoka N et coll: Acute, subacute and chronic toxicity studies on gliclazide, a new sulfonylurea derivative *Jpn Pharmacol Ther* 1980; **8**(8):41-69
26. Quatraro A, Consoli G, Ceriello A, Giugliano D: Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one-year follow-up *Diabete Metab* 1986; **12**:315-318

27. Regnault F: Gliclazide in the treatment of diabetic retinopathy
Adv Exp Med Biol 1979; **119**:443-448
28. Serradas P, Bailbe D, Portha B: Long-term gliclazide treatment improves the in-vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin *Diabetologia* sept. 1989; sous presse
29. Shimizu M, Tsuboi J, Fujitani B et coll: Pharmacological studies on gliclazide. Effects of gliclazide on platelet aggregation, adhesion and blood coagulation *Pharmacometrics* 1976; **12**(2):295-302
30. Tourniaire J, Orgiazzi J: Gliclazide and thyroid function, an experimental and clinical study
Royal Soc Med Int Congr Symp 1980:151-155
31. Tsuboi T, Fujitani B, Maeda J et coll: Effect of gliclazide on prostaglandin and thromboxane synthesis in guinea pig platelets *Thromb Res* 1981; **21**:103-110
32. Turner RC, Hoskerj P, Rudenski AS, Burnett MA, Matthews DR: Similar reduction of first and second phase B-cell responses at three different glucose levels in type II diabetes, and the effect of gliclazide therapy *Metabolism* 1989; **38**(5):107-110
33. Product Monograph for ^{Pr}DIAMICRON[®], revised October 21, 2016. Servier Canada Inc. Control No. 197558.